'Real Science'

As a behavioral scientist (health psychologist) who has had funding from NIH for 25 years, I find many reports appearing in The Scientist to be of interest. I found the ‘piece “Project 2061: A Place To Start Educating The Public” (Aug. 7, 1989, page 1 1) especially interesting. Having served on two NIH multi-disciplinary study sections, as an ad hoc member of a number of other NIH review committees, and on intrauniversity review committees at two universities, I can declare

Written byStephen Kegeles
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As a behavioral scientist (health psychologist) who has had funding from NIH for 25 years, I find many reports appearing in The Scientist to be of interest. I found the ‘piece “Project 2061: A Place To Start Educating The Public” (Aug. 7, 1989, page 1 1) especially interesting. Having served on two NIH multi-disciplinary study sections, as an ad hoc member of a number of other NIH review committees, and on intrauniversity review committees at two universities, I can declare that science is primarily a way of looking at and dealing with the world.

However, on page 3 of the same issue as the one featuring the article on Project 2061 is a piece titled, “Patient Services Vie For Bigger Share Of AIDS Funds,” in which behavioral research is coupled with patient services, with the complaint being that these activities may take money away from “real” science. In fact, behavioral ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies